Article
Pharmacology & Pharmacy
Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Summary: The clinical efficacy of lenvatinib was compared between hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and hepatitis C virus (HCV)-related HCC. The study found that patients with HBV-HCC had higher objective response rate and disease control rate compared to HCV-HCC, but there were no significant differences in progression-free survival and overall survival between the two groups. Multivariate regression analysis identified HBV infection and antiviral time > 5 years as independent favorable factors for progression-free survival. Overall, lenvatinib seemed to be more effective in HBV-related HCC compared to HCV-related HCC.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biophysics
Ru Cheng, Fu Zhu, Min Huang, Qiang Zhang, Hui Hong Yan, Xiao Hui Zhao, Fu Kang Luo, Chun Mei Li, Hui Liu, Gao Lin Liang, Cheng Zhi Huang, Jian Wang
Summary: In this study, a new biosensor named hepatitis virus indicator was developed for the simultaneous detection of HBV and HCV. The biosensor utilized Exo III assisted signal amplification strategy and particle counting technology with a dark-field microscopy, enabling sensitive and selective detection.
BIOSENSORS & BIOELECTRONICS
(2022)
Review
Gastroenterology & Hepatology
Corey Saraceni, John Birk
Summary: Despite advances in therapy, HBV and HCV remain significant global health burdens, leading to cirrhosis, hepatocellular carcinoma, and death worldwide. The development of HBV vaccine has greatly reduced spread of the virus, while new direct acting antivirals have improved treatment for HCV. However, challenges such as treatment failures and limitations in vaccine efficacy still exist.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S. Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson
Summary: A meta-analysis was conducted on clinical outcomes after nucleot(s)ide analogue (NA) discontinuation for HBeAg-negative CHB patients, revealing that virological relapse is common but clinical relapse occurs in only one-third of patients at 12 months post-NA discontinuation. Discontinuation of NA therapy can lead to HBsAg clearance, with higher rates observed with longer follow-up periods.
Article
Medicine, General & Internal
Jun Li, Zhao Wu, Gui-Qiang Wang, Hong Zhao
Summary: The study revealed correlations between HBcrAg and antiviral efficacy, virological, and histological variables in chronic hepatitis B patients, with a decreased HBcrAg predicting HBeAg loss after antiviral therapy.
CHINESE MEDICAL JOURNAL
(2021)
Article
Mathematics, Applied
John B. H. Njagarah, Farai Nyabadza, Moatlhodi Kgosimore, Cang Hui
Summary: The study focused on the dynamics of HBV and HCV infections in the liver and blood cells, considering immune responses and antiviral therapy. Results suggest that highly effective antiviral therapy to block virion production is crucial in containing infections.
APPLIED MATHEMATICS AND COMPUTATION
(2021)
Article
Immunology
Nicole E. Skinner, Clinton O. Ogega, Nicole Frumento, Kaitlyn E. Clark, Srinivasan Yegnasubramanian, Kornel Schuebel, Jennifer Meyers, Anuj Gupta, Sarah Wheelan, Andrea L. Cox, James E. Crowe Jr, Stuart C. Ray, Justin R. Bailey
Summary: By analyzing the B cell receptors (BCRs) of HCV-infected individuals, researchers identified distinctive BCR features associated with broad neutralization of HCV. These features include long heavy chain complementarity determining region 3 (CDRH3) regions, specific VH gene usage, increased frequencies of somatic hypermutation, and particular VH gene mutations. Further study of these antibodies can inform HCV vaccine development.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Health Care Sciences & Services
Joerg F. Schlaak
Summary: The majority of chronic viral hepatitis cases are caused by HBV, HCV, or HDV infections. HBV infection can be controlled with currently available drugs, but a functional cure is rare. HCV treatment has been revolutionized by the development of DAAs, which are highly effective and have few side effects. HDV remains the most challenging type of viral hepatitis to treat.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Erkin Musabaev, Chris Estes, Shakhlo Sadirova, Shokhista Bakieva, Krestina Brigida, Rick Dunn, Shyamasundaran Kottilil, Poonam Mathur, Ameer Abutaleb, Kathryn Razavi-Shearer, Tim Anstiss, Bakhodir Yusupaliev, Homie Razavi
Summary: Chronic infection with HBV and HCV is a major cause of liver disease and mortality in Uzbekistan. This study demonstrated the feasibility of large-scale simplified testing and treatment to implement a national viral hepatitis elimination program.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Yang Wang, Qiqi Li, Cheng Li, Cong Wang, Shijie Wang, Wenjie Yuan, Demin Yu, Ke Zhang, Bisheng Shi, Xiaomei Chen, Tiantian Liu, Zhenghong Yuan, Shuping Tong, Michael Nassal, Yu-Mei Wen, Yong-Xiang Wang
Summary: We developed multiple CARs targeting HBV envelope proteins and investigated their effects on HBsAg secretion and HBV infection using various cell culture models and HBV mouse models. We found that these CARs could block HBV infection and virion secretion, and G12-CARs could also inhibit HBsAg secretion. In HBV mouse models, G12-CAR-Fc strongly suppressed serum HBsAg levels.
Article
Gastroenterology & Hepatology
Po-Yao Hsu, Yu-Ju Wei, Po-Cheng Liang, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ching- Huang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Ming-Lun Yeh, Chung-Feng Huang, Yi-Wen Chiu, Shang-Jyh Hwang, Wan-Long Chuang, Ming-Lung Yu
Summary: Hemodialysis patients are at increased risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. This study found that hemodialysis patients with HCV exhibited a higher burden of comorbidities, especially in ischemic heart diseases, respiratory disorders, and mental/behavioral disorders, compared to patients with HBV and those without viral hepatitis.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jordan J. Feld, Anna S. Lok, Fabien Zoulim
Summary: Current therapy for chronic hepatitis B rarely achieves a functional cure, but novel treatments are being developed. Understanding the mechanisms of hepatitis B virus persistence has helped identify new treatment targets and evaluate novel agents in clinical trials. Combining different agents appears to be a promising strategy to reduce viral replication, invigorate immune responses, and induce specific adaptive immune responses.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Ming-Tsung Lin, Kuo-Chin Chang, Yi-Hao Yen, Ming-Chao Tsai, Chien-Hung Chen, Jing-Houng Wang, Chang-Chun Hsiao, Yueh-Hsia Chiu, Tsung-Hui Hu
Summary: The study found that patients with chronic hepatitis B are at higher risk of developing hepatocellular carcinoma compared to those with chronic hepatitis C after achieving virological response. Special attention should be paid to these patients.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2021)
Article
Biophysics
Suchanat Boonkaew, Abdulhadee Yakoh, Nattaya Chuaypen, Pisit Tangkijvanich, Sirirat Rengpipat, Weena Siangproh, Orawon Chailapakul
Summary: Electrochemical paper-based analytical devices (ePADs) are simple, portable, and low-cost analytical devices for point-of-care testing of clinical biomarkers. A sequential ePAD has been developed for simultaneous detection of hepatitis B surface antigen and hepatitis C core antigen by integrating dual flow behaviors, avoiding the need for complex multi-step reagent manipulation by the user. The proposed ePAD shows high promise as an easy-to-use, portable, and extendable sensor for other multiplex biological assays.
BIOSENSORS & BIOELECTRONICS
(2021)
Article
Gastroenterology & Hepatology
Hye-Lin Kim, Gi-Ae Kim, Jae-A Park, Hye-Rim Kang, Eui-Kyung Lee, Young-Suk Lim
Summary: This study found that starting antiviral therapy in the immune-tolerant phase is more cost-effective compared with delaying treatment until the active hepatitis phase in CHB patients, especially with increasing hepatocellular carcinoma risk, decreasing drug costs, and consideration of productivity loss.
